Navigation Links
Common Heart Drug Might Dampen Some Autism Symptoms
Date:12/11/2012

By Serena Gordon
HealthDay Reporter

TUESDAY, Dec. 11 (HealthDay News) -- A medication typically prescribed to control high blood pressure that's commonly referred to as a water pill may ease some of the symptoms of autism, researchers say.

That's especially true for people who have milder forms of the disorder, the new research indicates.

"Bumetanide is a promising novel therapeutic agent to treat autism," wrote the study's authors, who were quick to point out that this treatment is not a cure for autism and that larger trials need to be done to determine who would benefit most from this treatment.

Results of the study appear online Dec. 11 in the journal Translational Psychiatry.

Autism is a developmental disorder that results in communication problems, social difficulties, repetitive behaviors and restricted interests, according to background information in the study. The exact cause of the disorder isn't yet known, though genetic and environmental factors are believed to play a role.

Scientists have also studied neurotransmitters, suspecting that these chemical messengers in the brain might not be working as they should in people with autism. Gamma-aminobutyric acid (GABA) is one such neurotransmitter, and the medication bumetanide appears to be able to alter the function of GABA, at least in animals, according to the researchers.

In this latest study, the researchers gave 60 children who had been diagnosed with autism or Asperger's syndrome either 1 milligram of bumetanide or an inactive placebo pill daily. All of the children were between 3 and 11, and the study period lasted three months.

The severity of autism was determined by videotaped evaluations done on the first day of the study and the 90th day, by researchers who didn't know which children had received active treatment and which had been given a placebo pill.

Using several standardized autism assessment tools, the researchers found that bumetanide improved autism symptoms. The effects of the medication were more pronounced in children with milder autism. In case reports included in the study, some of the improvements seen included more eye contact, improved non-verbal communication and better social communication.

Side effects were very mild, though the use of the drug does require periodic monitoring for potassium levels; one child in the study had low potassium levels.

Senior study author Yehezkel Ben-Ari, founder of the Institute of Neurobiology of the Mediterranean Sea in Bohars, France, said the authors believe that the improvement in symptoms is due to an effect on GABA caused by the drug.

One expert said the findings look promising.

"This is a very interesting study. The authors have taken a medication that's been on the back shelf for decades and, surprisingly, found a clinically significant benefit when used in children with autism, especially those on the milder end of the spectrum," noted Dr. Andrew Adesman, chief of developmental and behavioral pediatrics at the Steven and Alexandra Cohen Children's Medical Center of New York in New Hyde Park, N.Y.

"Children would need to be on this medication indefinitely, because their improvements deteriorate when the medication is stopped. And, we don't yet know if there are any long-term concerns," he said. "Hopefully, this study will be a catalyst to new research. We need to see additional studies before we can recommend this treatment widely, but since it's already FDA-approved, we should know more in just a few years."

More information

To learn more about autism, visit the U.S. Department of Health and Human Services.

SOURCES: Yehezkel Ben-Ari, Ph.D., founder, Institute of Neurobiology of the Mediterranean Sea, Bohars, France; Andrew Adesman, M.D., chief, developmental and behavioral pediatrics, Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, N.Y.; Dec. 11, 2012, Translational Psychiatry, online


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Kids With Autism Common Users of ERs, Study Says
2. At Least 35 Common Medical Conditions are Contraindicated for Certain Yoga Poses: Prevent Yoga Injury Campaigns to Educate on Yoga Safety
3. Researchers report first success of targeted therapy in most common non-small cell lung cancer
4. Overactive Thyroid May Raise Risk for Common Irregular Heartbeat
5. Kentucky study finds common drug increases deaths in atrial fibrillation patients
6. Mans best friend: Common canine virus may lead to new vaccines for deadly human diseases
7. Costly, Repeat Medical Testing Common for Medicare Patients: Study
8. Obese but happy gene challenges the common perception of link between depression and obesity
9. Study suggests repeat testing common among medicare beneficiaries
10. Genital Injuries Common But Preventable, Researchers Say
11. Study overturns common assumption about knee replacements in morbidly obese individuals
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Common Heart Drug Might Dampen Some Autism Symptoms
(Date:7/21/2017)... ... July 21, 2017 , ... Hospital M&A activity slowed ... . The number of hospital acquisitions rose to 23 in the second quarter, up ... up 15% from the 20 announced deals in the year-ago second quarter. Only four ...
(Date:7/21/2017)... NJ (PRWEB) , ... July 21, 2017 , ... ... has received a $5,000 grant from the C. R. Bard Foundation, ... Day Center at Somerset Hills , a service available through the nonprofit home ...
(Date:7/21/2017)... ... , ... West Dermatology is pleased to announce the newest addition to their ... Vu will join West Dermatology’s large network of medical and cosmetic dermatology practices, bringing ... and more. She graduated from the University of Florida College of Medicine Physician Assistant ...
(Date:7/20/2017)... ... , ... TransPixel Volume 2 is a set of transitions that create a ... isolates horizontal and vertical lines of pixels and sorts their pixels by darkness, brightness, ... and can be changed using a drop-down menu. Create amazing and artistic transitions using ...
(Date:7/20/2017)... ... July 20, 2017 , ... Coats Rose, P.C. , ... announce their expansion to the Midwest with the establishment of the firm’s new ... Bell, and of counsels, John Peck and Robert Bruns, will establish and anchor ...
Breaking Medicine News(10 mins):
(Date:6/30/2017)... , June 30, 2017 In vitro ... the start of May, at least ten diagnostic companies ... private investments, public offerings and a loan facility.  The ... to almost $80 million.  Kalorama Information provides a monthly ... its Diagnostics Knowledge Center. ...
(Date:6/30/2017)... HIGH POINT, N.C. , June 29, 2017  Axium Pharmaceuticals ... innovations for developing improved novel formulations and alternative dosage forms ... ... transmucosal delivery is based on our waterless self-nano emulsifying formula, ... after contact with saliva. We believe the spray will provide ...
(Date:6/27/2017)... , Jun 27, 2017   NuEyes (NuEyes Technologies ... funding to fuel its growth in helping the legally blind ... (Osterhout Design Group), the leading developer of augmented, virtual and ... sits. The undisclosed funding amount was provided by ... Arab Angel, with offices in Abu Dhabi ...
Breaking Medicine Technology: